Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon
- PMID: 30181415
- DOI: 10.6004/jnccn.2018.7043
Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon
Abstract
Mutations in the RAS/RAF/MEK/ERK pathway leading to constitutive activation and uncontrolled cellular growth have been identified in various human malignancies, making this pathway a target for potential therapeutics. The activating BRAFV600E mutation is one well-characterized oncogenic mutation that has been described and targeted with clinical success in various malignancies, including melanoma and hairy cell leukemia. Although BRAF-directed treatments have yielded clinical benefit in a subset of tumor types, such as melanoma, thyroid cancer, and lung cancer, BRAF inhibition fails to confer a clinical benefit in colon cancer. Identification of patients for whom BRAF inhibition may produce clinically meaningful outcomes is imperative. The incidence of BRAF mutations in neuroendocrine carcinoma (NEC) is estimated to be 5% to 10%. A recent case series demonstrated benefit in targeting the BRAFV600E mutation in metastatic high-grade rectal NECs. Combination BRAF and MEK inhibition is known to yield improved outcomes compared with BRAF inhibition alone in melanoma. This report presents 2 patients with high-grade colorectal NECs who had different responses to treatment with combined BRAF/MEK inhibition after experiencing disease progression through first-line platinum-based chemotherapy. One patient experienced an excellent initial response to therapy before ultimately experiencing progression, and in the other patient initially had stable disease before eventually experiencing progression. These cases highlight the complicated role BRAF mutations play in gastrointestinal NECs, and the need for further research to identify not only patients who may benefit from BRAF-directed therapies but also strategies to avoid development of resistance.
Trial registration: ClinicalTrials.gov NCT01713972 NCT01885195.
Copyright © 2018 by the National Comprehensive Cancer Network.
Similar articles
-
BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.Int J Cancer. 2019 Mar 15;144(6):1379-1390. doi: 10.1002/ijc.31828. Epub 2018 Oct 30. Int J Cancer. 2019. PMID: 30144031
-
The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.J Cell Physiol. 2018 Mar;233(3):2162-2169. doi: 10.1002/jcp.25952. Epub 2017 May 23. J Cell Physiol. 2018. PMID: 28407239 Review.
-
BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Cancer Discov. 2016 Jun;6(6):594-600. doi: 10.1158/2159-8290.CD-15-1192. Epub 2016 Apr 5. Cancer Discov. 2016. PMID: 27048246 Free PMC article.
-
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X. Lancet Oncol. 2015. PMID: 26433819 Clinical Trial.
-
Resistance to BRAF-targeted therapy in melanoma.Eur J Cancer. 2013 Apr;49(6):1297-304. doi: 10.1016/j.ejca.2012.11.019. Epub 2013 Jan 2. Eur J Cancer. 2013. PMID: 23290787 Review.
Cited by
-
Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.J Gastrointest Cancer. 2024 May 30. doi: 10.1007/s12029-024-01072-0. Online ahead of print. J Gastrointest Cancer. 2024. PMID: 38814411
-
Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.Ups J Med Sci. 2024 Apr 10;129. doi: 10.48101/ujms.v129.10660. eCollection 2024. Ups J Med Sci. 2024. PMID: 38716076 Free PMC article.
-
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas.Chin J Cancer Res. 2024 Feb 29;36(1):90-102. doi: 10.21147/j.issn.1000-9604.2024.01.09. Chin J Cancer Res. 2024. PMID: 38455367 Free PMC article.
-
Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma.Cancers (Basel). 2023 Oct 11;15(20):4951. doi: 10.3390/cancers15204951. Cancers (Basel). 2023. PMID: 37894318 Free PMC article. Review.
-
Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.Cancer Metastasis Rev. 2023 Sep;42(3):1021-1054. doi: 10.1007/s10555-023-10121-2. Epub 2023 Jul 8. Cancer Metastasis Rev. 2023. PMID: 37422534 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous